Abstract
A general method is presented for the identification of radiometabolites in plasma of human and monkey subjects after administration of positron emission tomography (PET) radioligands. The radiometabolites are first produced in vitro, using liver microsomes, subsequently separated using fast radio-liquid chromatography (radio-LC), and individually collected and identified by ultra high-performance liquid chromatography/quadrupole-time of flight-mass spectrometry in MS and MSE mode. Fast radio-LC provided superior resolution compared to conventional radio-LC, resulting in separation of a greater number of metabolites. The radiometabolites produced in vivo are then compared to and identified based on the in vitro results. This approach was applied to three PET radioligands, [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28, resulting in the identification of five, two, and one radiometabolites, respectively. This procedure can easily be adopted to identify the radiometabolites produced in vivo from a variety of PET radioligands.
Similar content being viewed by others
References
Halldin C, Swahn C-G, Farde L, Sedvall G (1995) In: Comar D (ed) PET for drug development and evaluation. Kluwer Academic, Netherlands
Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA (2001) Synapse 41:11–21
Osman S, Lundkvist C, Pike VW, Halldin C, McCarron JA, Swahn CG, Ginovart N, Luthra SK, Bench CJ, Grasby PM, Wikström H, Barf T, Cliffe IA, Fletcher A, Farde L (1996) Nucl Med Biol 23:627–634
Osman S, Lundkvist C, Pike VW, Halldin C, McCarron JA, Swahn C-G, Farde L, Ginovart N, Luthra SK, Gunn RN, Bench CJ, Sargent PA, Grasby PM (1998) Nucl Med Biol 25:215–223
Giron MC, Portolan S, Bin A, Mazzi U, Cutler CS (2008) Q J Nucl Med Mol Imaging 52:254–266
Shetty HU, Zoghbi SS, Liow J-S, Ichise M, Hong J, Musachio JL, Halldin C, Seidel J, Innis RB, Pike VW (2007) Eur J Nucl Med Mol Imaging 34:667–678
Ma Y, Kiesewetter DO, Lang L, Gu D, Chen X (2010) Curr Drug Metab 11:483–493
Nakao R, Schou M, Halldin C (2012) J Chromatogr B 895–896:116–122
Hantraye P, Kaijima M, Prenant C, Guibert B, Sastre J, Crouzel M, Naquet R, Comar D, Maziere M (1984) Neurosci Lett 48:115–120
Persson A, Ehrin E, Eriksson L, Farde L, Hedström C-G, Litton J-E, Mindus P, Sedvall G (1985) J Psychiatry Res 19:609–622
Halldin C, Stone-Elander S, Thorell JO, Persson A, Sedvall G (1988) Appl Radiat Isot 39:993–997
Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C (2009) Bioorg Med Chem Lett 19:4843–4845
Briard E, Zoghbi SS, Imaizumi M, Gourley JP, Shetty HU, Hong J, Cropley V, Fujita M, Innis RB, Pike VW (2008) J Med Chem 51:17–30
Nagren K, Halldin C (1998) J Label Compd Radiopharm 41:831–841
Briard E, Hong J, Musachio JL, Zoghbi SS, Fujita M, Imaizumi M, Cropley V, Innis RB, Pike VW (2005) J Label Compd Radiopharm 48:S71
Stepanov V, Krasikova R, Raus L, Loog O, Hiltunen J, Halldin C (2012) J Label Compd Radiopharm 55:206–210
Ma Y, Lang L, Kiesewetter D, Jagoda E, Eckelman WC (2006) Nucl Med Biol 33:1013–1019
Bonn B, Leandersson C, Fontaine F, Zamora I (2010) Rapid Commun Mass Spectrom 24:3127–3138
Levêque P, De Hoffmann E, Labar D, Gallez B (2001) J Chromatogr B 754:35–44
Persson A, Pauli S, Swahn C-G, Halldin C, Sedvall G (1989) Hum Psychopharmacol 4:215–220
Swahn C-G, Persson A, Paulis S (1989) Hum Psychopharmacol 4:297–301
Debruyne D, Abadie P, Barre L, Albessard F, Moulin M, Zarifian E, Baron JC (1991) Eur J Drug Metab Pharmacokinet 16:141–152
Prasad B, Garg A, Takwani H, Singh S (2011) Trends Anal Chem 30:360–387
Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, Gulyás B, Halldin C (2009) Synapse 63:871–880
Varrone A, Tóth M, Steiger C, Takano A, Guilloteau D, Ichise M, Gulyás B, Halldin C (2011) J Nucl Med 52:132–139
Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, Hong J, Pike VW, Innis RB (2008) NeuroImage 40:43–52
Imaizumi M, Briard E, Zoghbi SS, Gourley JP, Hong J, Fujimura Y, Pike VW, Innis RB, Fujita M (2008) NeuroImage 39:1289–1298
Pike VW (2009) Trends Pharmacol Sci 30:431–440
Somers GI, Harris AJ, Bayliss MK, Houston JB (2007) Xenobiotica 37:832–854
De Graaf IAM, Van Meijeren CE, Pektas F, Koster HJ (2002) Drug Metab Disp 30:1129–1136
Acknowledgments
The authors thank all the members of the PET group at Karolinska Institutet for their kind assistance during this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amini, N., Nakao, R., Schou, M. et al. Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28. Anal Bioanal Chem 405, 1303–1310 (2013). https://doi.org/10.1007/s00216-012-6541-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-6541-2